vindesine/fever

The link is saved to the clipboard

ArticlesClinical trialsPatents

Choose sort type

Page 1 from 42 results

[Phase II study of vindesine in hematological malignancies].

Only registered users can translate articles

A Phase II study of vindesine was carried out by the Vindesine Study Group in 130 patients with hematological malignancies: mainly 3 mg/body (about 2 mg/m2) of vindesine was administered once weekly by bolus injection. In 122 evaluable patients who had been heavily pretreated with vincristine and/or

[Phase II study of vindesine in patients with carcinoma of the lung and metastatic pulmonary tumor].

Only registered users can translate articles

A phase II study of Vindesine (VDS) was carried out in 20 patients with carcinoma of the lung (14 adenocarcinomas, 3 squamous cell carcinomas, 2 large cell carcinomas and 1 small cell carcinoma), and in 18 patients with metastatic pulmonary tumor (primary organ: 4 colons, 2 uteri, 2 lungs, one each

[Administration of vindesine sulfate for the treatment of malignant hematological tumors].

Only registered users can translate articles

Forty-six cases with hematological malignancies were treated with vindesine sulfate (VDS); a new semisynthetic vinca alkaloid. Six cases with ALL, 5 cases CML in blastic crisis, 3 Hodgkin's disease (HD) and 4 non-Hodgkin's lymphoma (NHL) were treated with VDS alone. Five out of 6 cases ALL, 2 out of

[A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].

Only registered users can translate articles

A multicenter cooperative study was performed to compare KW-2307 (KW), a novel vinca alkaloid (VA) derivative, and vindesine (VDS), with respect to tumor response and toxicity in patients (pts) with non-small cell lung cancer. In the former part of the trial, pts received monotherapy with KW 25

Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.

Only registered users can translate articles

A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. There was one complete remission (2.5%) of greater than 12 months duration; seven partial remissions (17.5%) of two, three, three, four, five, six

Effect of temperature on the cytotoxicity of vindesine, amsacrine, and mitoxantrone.

Only registered users can translate articles

The effect of elevated temperature on the cytotoxicity of three new anticancer drugs (vindesine, mitoxantrone, and amsacrine [AMSA]) was tested in Chinese hamster ovary cells in vitro. Three distinct patterns of interaction with hyperthermia were observed. Vindesine, tested at 37 degrees C, produced

Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion.

Only registered users can translate articles

Sixty patients with metastatic breast cancer refractory to prior doxorubicin combinations were randomized by performance status, dominant disease site, and number of involved organ sites to receive vindesine either as a bolus injection of 3-4 mg/m2 iv every 10-14 days or as a continuous 5-day

Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer.

Only registered users can translate articles

OBJECTIVE A phase II study of nedaplatin and vindesine was conducted to evaluate their efficacy and safety for treatment of relapsed or refractory non-small-cell lung cancer (NSCLC). METHODS Between August 1996 and September 1998, 48 patients who had previously received chemotherapy, thoracic

[A phase II study of vindesine for pretreated non-small cell lung cancer].

Only registered users can translate articles

A phase II evaluation of vindesine (VDS) was performed in 16 patients with non-small cell lung cancer (ten patients with adenocarcinoma, six patients with squamous cell carcinoma, and one patient with large cell carcinoma). All except one of the patients had had prior chemotherapy. VDS at a dose of

[Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma].

Only registered users can translate articles

OBJECTIVE To investigate the clinical efficacy of bleomycin, cyclophosphamide, vindesine, Ara-C and dexamethasone(BACOD) for treatment of patients with relapsed/refractory diffuse large B cell lymphoma. METHODS A total of 56 patients with relapsed/refractory diffuse large B cell lymphoma were

Vindesine in the treatment of metastatic breast cancer.

Only registered users can translate articles

Thirty-five patients with advanced metastatic breast cancer refractory to prior chemotherapy were treated with vindesine given at a fixed dose as a continuous 5-day infusion of 1.5 mg/day every 4 weeks. All patients were considered evaluable, and there were four patients with partial responses for

Vindesine in the treatment of esophageal carcinoma: a phase II study.

Only registered users can translate articles

Vindesine, a new vinca alkaloid, has shown therapeutic activity in several human malignancies. A phase II study in 26 patients with squamous cell carcinoma of the esophagus was performed. Sixty percent of these patients had received prior chemotherapy. The starting dose was 3.0 mg/m2, which was

Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia.

Only registered users can translate articles

Vinca alkaloids are effective anticancer agents. Vindesine is a recent vinca alkaloid derivative with anti-tumor effects shown in in vitro systems and in patients with acute lymphocytic leukemia (ALL). The present study was designed to investigate the therapeutic effectiveness and toxicity of

Evaluation of vindesine and MER in colorectal cancer.

Only registered users can translate articles

Vindesine, a derivative of vinblastine, was administered to 39 patients with advanced colorectal cancer refractory to 5-fluorouracil alone or in combination with other chemotherapeutic agents. The initial dose of vindesine was 4 mg/m2 administered intravenously (IV) over 30 minutes every two weeks.

[A case of Ewing's sarcoma treated successfully by combination chemotherapy consisting of high-dose methotrexate, aclacinomycin-A and vindesine].

Only registered users can translate articles

A 22-year-old man was admitted to Kyushu University Hospital because of high fever, and pain in the right foot and back. An X-ray examination revealed an osteolytic lesion on the 5th metatarsal bone of the right foot. Paraplegia and disturbance of bladder function occurred and compression of the

Join our facebook page

Herbal & Natural Medicine

The most complete medicinal herbs database backed by science

Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research